BRPI0718945B8 - novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção - Google Patents

novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Info

Publication number
BRPI0718945B8
BRPI0718945B8 BRPI0718945A BRPI0718945A BRPI0718945B8 BR PI0718945 B8 BRPI0718945 B8 BR PI0718945B8 BR PI0718945 A BRPI0718945 A BR PI0718945A BR PI0718945 A BRPI0718945 A BR PI0718945A BR PI0718945 B8 BRPI0718945 B8 BR PI0718945B8
Authority
BR
Brazil
Prior art keywords
methods
production
water solubility
resistance against
increased metabolism
Prior art date
Application number
BRPI0718945A
Other languages
English (en)
Portuguese (pt)
Inventor
Ragagnin Gianna
Bäckström Torbjörn
Original Assignee
Umecrine Ab
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab, Umecrine Cognition Ab filed Critical Umecrine Ab
Priority to BR122013033954A priority Critical patent/BR122013033954B8/pt
Publication of BRPI0718945A2 publication Critical patent/BRPI0718945A2/pt
Publication of BRPI0718945A8 publication Critical patent/BRPI0718945A8/pt
Publication of BRPI0718945B1 publication Critical patent/BRPI0718945B1/pt
Publication of BRPI0718945B8 publication Critical patent/BRPI0718945B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0718945A 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção BRPI0718945B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013033954A BR122013033954B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
US60/860,658 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (4)

Publication Number Publication Date
BRPI0718945A2 BRPI0718945A2 (pt) 2013-12-24
BRPI0718945A8 BRPI0718945A8 (pt) 2017-09-19
BRPI0718945B1 BRPI0718945B1 (pt) 2020-10-13
BRPI0718945B8 true BRPI0718945B8 (pt) 2021-05-25

Family

ID=39429970

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0718945A BRPI0718945B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção
BR122013033954A BR122013033954B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122013033954A BR122013033954B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Country Status (16)

Country Link
US (9) US8580983B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP2711371B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP5386362B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2007322423C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0718945B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2664126C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK2097437T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2662500T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE033037T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN02014A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2009005335A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL2792681T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2097437E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2458065C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2097437T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2008063128A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664126C (en) 2006-11-21 2014-04-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
AU2011205821B2 (en) 2010-01-14 2013-07-25 Relmada Therapeutics, Inc. A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
WO2011138460A1 (en) * 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof
EP4245369A3 (en) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI2925770T1 (sl) * 2012-11-28 2017-07-31 Institut National De La Sante Et De La Recherche Medicale(Inserm) 3-(4'-substituirani)-benzil-eter derivati pregnenolona
SI3461834T1 (sl) 2013-03-13 2021-11-30 Sage Therapeutics, Inc. Nevroaktivni steroidi
SI3099306T1 (sl) * 2014-01-29 2019-03-29 Umecrine Cognition Ab Steroidna spojina za uporabo v zdravljenju hepatične encefalopatije
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HRP20200840T1 (hr) * 2014-11-27 2020-11-13 Sage Therapeutics, Inc. Pripravci i postupci za liječenje poremećaja cns-a
TWI748936B (zh) * 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
RU2021100377A (ru) 2015-07-06 2021-05-18 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CA2991214C (en) 2015-07-06 2024-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
CA3019146C (en) 2016-04-01 2024-03-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
IL297804A (en) 2016-10-18 2022-12-01 Sage Therapeutics Inc Oxysterols and methods of using them
IL293231B1 (en) 2016-10-18 2025-06-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
EP3579843A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN MEDICAL TREATMENT
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
WO2019102040A1 (en) 2017-11-27 2019-05-31 Umecrine Cognition Ab PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME
RU2020130861A (ru) 2018-04-05 2022-05-05 Асарина Фарма Апс Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
EP4430057A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) * 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT752860E (pt) * 1994-02-14 2000-12-29 Euro Celtique Sa Androstanos e pregnanos para modulacao alosterica do receptor de gaba
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
CA2223996A1 (en) 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
EP1063999B1 (en) 1998-03-11 2005-10-26 Torbjörn Backström Epiallopregnanolone in the treatment of cns disorders
WO1999052532A1 (en) 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) * 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
EP1812009B1 (en) * 2004-11-18 2013-05-15 Umecrine AB Gaba-steroid antagonists and their use for the treatment of cns disorders
CA2664126C (en) 2006-11-21 2014-04-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
WO2011138460A1 (en) 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
PT2097437E (pt) 2015-09-15
US20130281421A1 (en) 2013-10-24
US20080119416A1 (en) 2008-05-22
EP2792681A1 (en) 2014-10-22
JP2010510210A (ja) 2010-04-02
RU2009107537A (ru) 2010-12-27
ES2607852T3 (es) 2017-04-04
JP5386362B2 (ja) 2014-01-15
US20140011779A1 (en) 2014-01-09
IN2014DN02014A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-10
PL2792681T3 (pl) 2017-06-30
MX2009005335A (es) 2009-06-08
HUE033037T2 (hu) 2017-11-28
EP2097437B1 (en) 2015-05-27
US20130102579A1 (en) 2013-04-25
EP2711371B1 (en) 2018-01-10
US20160272670A1 (en) 2016-09-22
AU2007322423A1 (en) 2008-05-29
SI2097437T1 (sl) 2015-10-30
BR122013033954B8 (pt) 2021-05-25
BRPI0718945A2 (pt) 2013-12-24
DK2792681T3 (en) 2017-01-23
HUE026961T2 (en) 2016-07-28
BR122013033954B1 (pt) 2021-01-12
EP2792681B1 (en) 2016-10-19
WO2008063128A1 (en) 2008-05-29
CA2664126C (en) 2014-04-29
PL2711371T3 (pl) 2018-06-29
EP2711372A1 (en) 2014-03-26
EP2097437A1 (en) 2009-09-09
JP2013173781A (ja) 2013-09-05
US20150315231A1 (en) 2015-11-05
US8853190B2 (en) 2014-10-07
CA2833976A1 (en) 2008-05-29
AU2007322423C1 (en) 2013-08-15
BRPI0718945B1 (pt) 2020-10-13
DK2711371T3 (en) 2018-04-16
US20140011793A1 (en) 2014-01-09
US9200028B2 (en) 2015-12-01
ES2662500T3 (es) 2018-04-06
JP2013177411A (ja) 2013-09-09
US20140011792A1 (en) 2014-01-09
JP2013173782A (ja) 2013-09-05
US8580983B2 (en) 2013-11-12
DK2097437T3 (en) 2015-06-29
ES2543841T3 (es) 2015-08-24
JP5657052B2 (ja) 2015-01-21
JP5918170B2 (ja) 2016-05-18
CA2664126A1 (en) 2008-05-29
US20130102578A1 (en) 2013-04-25
PL2097437T3 (pl) 2015-12-31
EP2097437A4 (en) 2012-12-26
CA2833976C (en) 2016-03-15
JP2015147774A (ja) 2015-08-20
BRPI0718945A8 (pt) 2017-09-19
AU2007322423B2 (en) 2013-01-10
HUE036410T2 (hu) 2018-07-30
RU2458065C2 (ru) 2012-08-10
EP2711371A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
BRPI0718945B8 (pt) novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2007098281A3 (en) Oxysterol compounds and the hedgehog pathway
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
PT2044076E (pt) Processo de preparação de asenapina e de produtos intermediários utilizados no referido processo
IN2015DN00502A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2009061916A3 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
WO2007103468A3 (en) Use of vx-702 for treating rheumatoid arthritis

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UMECRINE COGNITION AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF